Concert Pharmaceuticals Other Current Liabilities

Concert Pharmaceuticals (CNCE) currently reports a other current liabilities of $5.7M as of September 2022. That compares with $7.6M in the prior-year period — down 24.8% year over year. Use the charts on this page to explore Concert Pharmaceuticals's other current liabilities history and peer comparisons.

Concert Pharmaceuticals's other current liabilities decreased from $7.6M to $5.7M — a 24.8% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Concert Pharmaceuticals reported $5.7M in other current liabilities as of September 2022. That compares with $7.6M in the prior-year period — down 24.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $5.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Concert Pharmaceuticals, and consider following CNCE for alerts when major investors trade the stock.

Concert Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $5.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CNCE with unrelated industries.